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Daptomycin is a lipopeptide antibiotic used as a last resort in the treatment of infections 61 caused by methicillin-resistant Staphylococcus aureus (MRSA) and vancomycin-resistant 62 enterococci (VRE) [1] [2] [3] . The use of daptomycin is becoming more common, with prescriptions 63 increasing 72 % between 2012 and 2015 in the UK [4] . Daptomycin is the only lipopeptide 64 antibiotic used clinically and functions in a similar manner to antimicrobial peptides [5] . The 65 antibiotic inserts into the membrane of Gram-positive bacteria by targeting 66 phosphatidylglycerol, where it forms oligomeric complexes [6] [7] [8] . The precise mechanism by 67 which the antibiotic kills bacteria is unclear, but involves depolarisation of the bacterial 68 membrane and inhibition of cell wall biosynthesis without causing lysis [8] [9] [10] [11] [12] [13] . Although 69 daptomycin resistance is rare, treatment failure occurs in up to 30 % of staphylococcal 70 infections and 23 % of enterococcal infections [14, 15] . Failure rates are highest in invasive 71 infections such as bacteraemia or osteomyelitis, with rates of 24 % and 33 % respectively, 72 resulting in poor patient prognoses [14] . Understanding the reasons for this treatment failure 73 is crucial to improving the effectiveness of daptomycin treatment. 74
We recently discovered that S. aureus has a transient defence mechanism against 75 daptomycin, which contributed to treatment failure in a murine model of invasive infection 76 [16] . In response to the antibiotic, phospholipids were released from the cell membrane 77 which sequestered daptomycin and abrogated its bactericidal activity [16] . Phospholipid 78 release occurred via an active process, which was blocked by the lipid biosynthesis inhibitor 79 platensimycin [16, 17] . In addition to daptomycin, phospholipid shedding also provided 80 protection against the antimicrobial peptides nisin and melittin, suggesting a general defence 81 against membrane-targeting antimicrobials [16] . 82
It is currently unknown whether other Gram-positive bacteria release phospholipids 83 in response to daptomycin, although membrane vesicles have been observed on the surface 84 of E. faecalis cells exposed to daptomycin [18] . In addition, there is growing evidence that 85 other Gram-positive pathogens, including Group A streptococci (GAS) and group B 86 streptococci (GBS), release phospholipids from their surfaces in the form of extracellular 87 vesicles [19, 20] . Production of these membrane vesicles is increased in the presence of 88 antimicrobials and, at least for GAS, are rich in phosphatidylglycerol, which was shown to be 89 essential for daptomycin inactivation by S. aureus [16, 19, 21] . Therefore, we hypothesised 90 that phospholipid release is a common strategy amongst Gram-positive pathogens to resist 91 membrane-acting antimicrobials. 92
Given the increasing use of daptomycin to treat enterococcal infections, the primary 93 aim of this work was to determine whether enterococci release membrane phospholipids that 94 inactivate the antibiotic. We also examined pathogenic streptococci, and S. epidermidis, as 95 the rising tide of antibiotic resistance may necessitate the use of daptomycin to tackle these 96 bacteria in the future. 97
We initially determined the daptomycin minimum inhibitory concentration (MIC) for 98 Hinton Broth containing calcium (0.5 mM) and MIC determined by the broth microdilution 102 approach [30]. The most susceptible species were the pathogenic GAS strain A40 (0.125 μg 103 ml -1 ), and GBS strains 515 (0.5 μg ml -1 ) and COH1 (0.5 μg ml -1 ), whilst S. aureus (1 μg ml -1 ), S. 104 epidermidis (1 μg ml -1 ), S. gordonii Challis (2-4 μg ml -1 ) E. faecalis strains OG1X (2 μg ml -1 ) and 105 JH2-2 (4 μg ml -1 ) were the least susceptible. 106
To determine whether E. faecalis or streptococci respond to daptomycin by releasing 107 membrane phospholipids, we exposed streptococci and enterococci (10 8 CFU ml -1 ) to various 108 supra-MIC concentrations of the antibiotic (5-40 μg ml -1 ) in Brain-Heart Infusion (0.5 mM 109
CaCl2) broth at 37 o C under static conditions with 5% CO2 and measured bacterial survival, 110 antibiotic activity and phospholipid release ( Fig. 1c-h ). Staphylococci were also exposed to 111 daptomycin (5-40 μg ml -1 ), but in tryptic soy broth (TSB) containing 0.5 mM CaCl2 at 37 o C with 112 shaking (180 RPM) ( Fig. 1a,b ). 113
For all strains, there was a dose-dependent decrease in survival after 8 h exposure to 114 daptomycin, as assessed by CFU counts (Fig. 1a-h ). However, as expected from the MIC data, 115 survival of the two enterococcal strains, the staphylococci and S. gordonii was greater than 116 survival of GAS or GBS strains at every concentration of daptomycin examined ( Fig. 1a-h) . 117
Using the phospholipid-reactive fluorescent dye FM-4-64 (Life Technologies), we 118 found that daptomycin triggered phospholipid release from all of the bacteria examined, 119 albeit to differing levels. The quantity of phospholipid released was much greater for 120 staphylococci than the other species examined ( Fig. 1i-p ). However, for both staphylococci 121 and streptococci, the quantity of phosphlipid released was lowest when the daptomycin 122 concentration was highest, suggesting that the antibiotic may have killed the bacteria before 123 they could release the lipid ( Fig. 1i-p) . By contrast, the enterococci released high levels of 124 phospholipid in the presence of the highest concentrations of daptomycin ( Fig. 1o,p ). This 125 may indicate different daptomycin concentration thresholds for triggering of phospholipid 126
release. 127
To determine whether phospholipid release resulted in the inactivation of 128 daptomycin, the activity of the antibiotic in the culture supernatants was measured using a 129 previously described zone of inhibition assay [16] ( Fig. 1q-x ). Daptomycin was inactivated to 130 varying degrees by the bacteria, depending on the concentration of the antibiotic used. 131
However, both staphylococcal strains, both enterococcal strains, S. gordonii and the GAS 132 strain completely inactivated daptomycin at 5 µg ml -1 , but GBS strains only partially 133 inactivated the antibiotic at this concentration. At 10 µg ml -1 daptomycin, only the 134 staphylococci, S. gordonii and the enterococci showed significant inactivation of the antibiotic 135
and at a concentration of 20 µg ml -1 daptomycin, only staphylococci and enterococci 136 inactivated the antibiotic to any significant degree, with a loss of 30-60% of antibiotic activity. 137
However, despite triggering phospholipid release, at 40 µg ml -1 daptomycin there was 138 relatively little (<20%) inactivation of the antibiotic by any of the bacteria tested. Therefore, 139 phospholipid release is finite and can be overcome with a sufficiently high dose of 140
daptomycin. 141
These data extend our previous finding that S. aureus releases phospholipid in 142 response to daptomycin and that this results in inactivation of the antibiotic by revealing a 143 very similar phenotype for S. epidermidis. These data also support the previous observation 144 that E. faecalis releases phospholipid in response to daptomycin [18] , and show that this 145 phospholipid release correlates with daptomycin inactivation and bacterial survival. 146
Streptococci, particularly S. gordonii, also released phospholipid and inactivated daptomycin, 147 albeit less efficiently than E. faecalis. Therefore, daptomycin-induced phospholipid release 148 appears to be a conserved mechanism across Gram-positive pathogens. 149
Next, we wanted to explore whether the mechanism of phospholipid release and 150 daptomycin inactivation by enterococci and streptococci was similar to that of S. aureus. 151
Therefore, we undertook further experiments with E. faecalis, which was most efficient of the 152 enterococci and streptococci at releasing phospholipid and inactivating daptomycin, and S. 153 aureus, in which daptomycin-triggered phospholipid release has been well characterised [16] . 154
In S. aureus, daptomycin-triggered phospholipid release is an active process that 155 requires energy, as well as protein and lipid biosynthesis [16] . To determine whether 156 phospholipid release by E. faecalis exposed to daptomycin was occurring via an active 157 process, or simply a consequence of damage caused by the antibiotic, bacteria were exposed 158 to the antibiotic in the presence or absence of a sub-inhibitory concentration of the 159 phospholipid biosynthesis inhibitor platensimycin [17] . As described previously, exposure of 160 S. aureus to daptomycin (10 µg ml -1 ) resulted in increased phospholipid in the supernatant 161 but this was significantly reduced in the presence of platensimycin at half the MIC (0.25 μg 162 ml -1 ) ( Fig. 2a) . Similarly, phospholipid was released upon exposure of E. faecalis to daptomycin 163 (10 µg ml -1 ), but this was blocked when platensimycin was present at half the MIC (0.5 μg ml -164 1 ) (Fig. 2b) . The presence of platensimycin prevented S. aureus from inactivating daptomycin 165 ( Fig. 2c ) and significantly reduced the ability of E. faecalis to inactivate daptomycin (Fig. 2d) . 166
This confirmed that daptomycin-induced phospholipid release by E. faecalis is an active 167 process that requires de novo lipid biosynthesis and is not simply a consequence of membrane 168 damage caused by the antibiotic. The ability of platensimycin to block phospholipid release 169 and prevent daptomycin inactivation by E. faecalis also provided strong evidence that, as for 170 S. aureus, daptomycin activity is blocked by the phospholipid in the supernatant. However, it 171 was necessary to rule out an alternative hypothesis; that the loss daptomycin inactivation was 172 simply due to binding of the antibiotic to the bacterial surface. 173
To measure binding of daptomycin to bacteria, daptomycin was labelled with the 174 Bodipy fluorophore (Life Technologies) as described previously [11, 16] . As reported 175 previously, a killing assay with E. facealis indicated that the labelled antibiotic had slightly 176 altered bactericidal activity relative to unlabelled daptomycin [11] (Fig 3a) . However, as 177 described above for unlabelled antibiotic (Fig. 1q,x) , the activity of the antibiotic decreased 178 after incubation with E. faecalis or S. aureus (Fig. 3b) , confirming that the Bodipy label does 179 not significantly affect the interaction of the antibiotic with the bacteria studied. 180
After 8 h incubation with Bodipy-daptomycin, bacterial cells were pelleted and the 181 fluorescence of both the cells and the supernatants was measured separately using a Tecan 182 microplate reader with excitation at 502 nm and emission at 510 nm. Antibiotic attachment 183
to the E. faecalis cellular fraction was similar for both Bodipy-daptomycin concentrations 184
examined, suggesting saturated binding to cells (Fig. 3c ). However, most of the antibiotic 185 remained in the supernatant (Fig. 3d ). By comparison, Bodipy-daptomycin bound S. aureus 186 more strongly than E. faecalis, with higher levels of fluorescence associated with bacterial 187 cells and a corresponding drop in the fluorescence of the supernatant (Fig. 3c,d ). This 188 difference in antibiotic binding may explain why the daptomycin MIC of the E. faecalis strains 189 used here (2-4 µg ml -1 ) is higher than that of the S. aureus strain examined (1 µg ml -1 ) and why 190 daptomycin triggers greater phospholipid release from staphylococci than enterococci. 191
Together, these data confirmed that the loss of daptomycin activity in E. faecalis 192 cultures was not due to binding of the antibiotic to the bacterial surface or the plastic vessels 193 used in the assays. However, as a final confirmation that phospholipid released from E. 194 faecalis inactivated daptomycin, we exposed the bacterium to daptomycin (5 µg ml -1 ) to 195 trigger phospholipid release, collected the cell-free culture supernatant and added a second 196 dose of the antibiotic (5 µg ml -1 ). The culture supernatant containing the released 197 phospholipids significantly reduced the activity of the second dose of daptomycin (by ~25%, 198 Fig. 3e ). Therefore, as described for S. aureus, the release of phospholipids by E. faecalis in 199 response to daptomycin inactivates the antibiotic. The data described above also indicate that 200 several species of streptococci release phospholipids in response to daptomycin, which 201 inactivate the antibiotic, albeit to a lesser extent than E. faecalis or S. aureus. 202
Streptococci and enterococci cause a range of serious diseases, including septicaemia 203 and endocarditis, which can be treated by daptomycin, especially when the pathogen is multi-204 drug resistant or the patient has a β-lactam allergy [1, 31] . The presence of this defence 205 mechanism in a variety of clinically-relevant Gram-positive bacteria indicates that it is 206 conserved and could be a viable target to improve the effectiveness of daptomycin therapy 207 against these pathogens. 208
In this work, we focussed on daptomycin because it is a last resort antibiotic and is 209 associated with high rates of treatment failure. However, whilst daptomycin use is increasing, 210 it is very unlikely to have provided the selection pressure for the evolution of the phospholipid 211 release defence mechanism described here and previously [16] . Since cationic antimicrobial 212 peptides (cAMPs) act via a similar mechanism to daptomycin in targeting the Gram-positive 213 cell membrane [5] we hypothesise that these host defence molecules have likely driven the 214 evolution of phospholipid release as a defence mechanism. 215
The discovery of phospholipid release in several Gram-positive pathogens expands our 216 growing appreciation of broad-spectrum extracellular defence mechanisms that protect 217 bacteria against antibiotics or host defences. For example, previous work has shown that the 218 production of outer-membrane vesicles by E. coli can protect against membrane-acting 219 antimicrobials such as polymixin E and colistin [32], whilst another report revealed that 220 lipochalins released by Burkholderia can sequester several different antibiotics [33] . These 221 findings underline the complex nature of innate antibiotic resistance, but also provide 222 opportunities for mechanistic insight and improved therapeutic approaches. For example, in 223 this report and previously, we have shown that inhibition of phospholipid biosynthesis using 224 platensimycin prevents the inactivation of daptomycin by both S. aureus and E. faecalis [16] . In summary, we have demonstrated that Enterococcus faecalis releases phospholipids 230 in response to daptomycin via an active mechanism requiring de novo lipid biosynthesis and 231 that these phospholipids inactivate daptomycin. Pathogenic streptococci also appear to be 232 capable of inactivating daptomycin by releasing phospholipids, indicating that this mechanism 233 is conserved amongst Gram-positive pathogens. 
